Moderna was creating a curriculum to inspire and educate learners about the opportunity mRNA presents as a medicine. The objective was to create an engaging online lecture that would serve both internal company training and public education. For XVIVO, it involved producing over 30 minutes of high-quality 3D animation focusing on mRNA technology, molecular and cellular processes, and therapeutic advancements.
XVIVO and Korro Bio continued their partnership to create an animation for Korro’s RNA editing oligonucleotide candidate for alpha-1 antitrypsin deficiency (AATD) from their proprietary OPERA™ platform.
Sonnet BioTherapeutics requested an animation to help explain how their Fully Human Albumin Binding (FHAB) platform functions and the potential benefits of the platform over existing anti-tumor therapies. With vivid colors and key lighting details, the FHAB is clearly the star of the show in this animation.
XVIVO recently partnered with Werewolf Therapeutics to create an animation about their INDUKINE molecules and how the molecules could transform immunotherapy as it is practiced today. Werewolf leadership had worked with XVIVO on a previous animation and really enjoyed the process and the final product. So it was an easy decision to pick a scientific animation studio when Werewolf needed help visualizing their science.
Ankyra Therapeutics teamed up with XVIVO on a scientific animation touting their anchored immunotherapy approach to cancer treatment, which is designed to promote prolonged immune activation at the tumor site while limiting systemic toxicity that can be associated with other immunotherapy.
Designed by BeiGene, Ociperlimab is an investigational monoclonal antibody designed to bind to TIGIT in an effort to combat cancer. Together with BeiGene we created an animation to support their groundbreaking work.
The Vaccine Makers Project, a program of the Vaccine Education Center at Children’s Hospital of Philadelphia (VEC@CHOP) and Medical History Pictures (MHP), partnered up again with XVIVO to help develop two new animations, this time about how COVID-19 mRNA and viral vector vaccines work.
Here, we’ll show you what went on behind the scenes to make the COVID-19 vaccine animations.
An illustration for Mirati Therapeutics depicts the molecular basis of a healthy state, a diseased state, and how their investigational agent MRTX123, targets the diseased state. As a static image, this illustration is layered with visual and scientific detail that hooks the viewer initially and makes them linger to fully absorb the complexity of the …
Cancers are marked by an elevated rate of cell replication; this is often a result of an abnormal presentation of particular cell signaling pathways. Some treatments for cancer modulate these overactive pathways by targeting certain pathway essential proteins, through inhibition of function, post-transcription modifications, gene therapy and epigenetic modulation.
The biopharmaceutical company Arvinas Inc. has taken a unique approach to develop investigational therapies for hard-to-treat diseases, including cancers. XVIVO, in collaboration with Wyant Simboli and their client, Arvinas Inc., helped communicate the unconventional mechanism of action for a new class of drugs that engage the body’s own protein disposal system to target cancers and …